apatinib + paclitaxel + platinum

A combination therapy regimen consisting of apatinib, an oral small-molecule tyrosine kinase inhibitor, and sequential chemotherapy with paclitaxel and a platinum-based agent (such as cisplatin or carboplatin). Apatinib selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2), thereby inhibiting tumor angiogenesis by blocking the VEGFR-2 tyrosine kinase activity. This specific combination is being evaluated by the Third Military Medical University in a Phase II single-arm clinical trial for patients with advanced, recurrent, or metastatic cervical cancer. The treatment protocol involves an initial lead-in phase of apatinib followed by standard chemotherapy cycles, with apatinib continued as maintenance therapy in the absence of disease progression.

Brand names

AiTan

Other names

apatinib mesylaterivoceranibapatinib + paclitaxel + cisplatinapatinib + paclitaxel + carboplatinapatinib-Third Military Medical University-cervical cancer